Intraocular inflammation is an important cause of blindness both in the developing and developed world. Corticosteroids play a pivotal role in the treatment of intraocular inflammation. Lately, therapy by immuno-suppr...Intraocular inflammation is an important cause of blindness both in the developing and developed world. Corticosteroids play a pivotal role in the treatment of intraocular inflammation. Lately, therapy by immuno-suppression has taken the center stage for patients with severe intraocular infammation. However, the side effects of immunosuppressive drugs are oncogenic, in-fectious, and hematological. Recently, biologic response modifiers specifically targeting suppression of the im-mune effector responses have revolutionized the treat-ment of intraocular infammation. Anti-tumour necrosis factor agents are etanercept, infiximab, and adalimum-ab. Newer drugs include certolizumab and golimumab. Infiximab has been found to be superior to corticoste-roids in treating retinal vasculitis. Anti-interlenkin thera-pies include rituximab, daclizumab, anakinra, tocilizum-ab and secukinumab. Rituximab has been proven to be quite effective. Other biologics used are interferons and abatacept. However, there are several limitations and side effects associated with their use.展开更多
文摘Intraocular inflammation is an important cause of blindness both in the developing and developed world. Corticosteroids play a pivotal role in the treatment of intraocular inflammation. Lately, therapy by immuno-suppression has taken the center stage for patients with severe intraocular infammation. However, the side effects of immunosuppressive drugs are oncogenic, in-fectious, and hematological. Recently, biologic response modifiers specifically targeting suppression of the im-mune effector responses have revolutionized the treat-ment of intraocular infammation. Anti-tumour necrosis factor agents are etanercept, infiximab, and adalimum-ab. Newer drugs include certolizumab and golimumab. Infiximab has been found to be superior to corticoste-roids in treating retinal vasculitis. Anti-interlenkin thera-pies include rituximab, daclizumab, anakinra, tocilizum-ab and secukinumab. Rituximab has been proven to be quite effective. Other biologics used are interferons and abatacept. However, there are several limitations and side effects associated with their use.
